Femasys: Ready To Turn The Corner (NASDAQ:FEMY) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NASHVILLE, Tenn., Feb. 17, 2021 /PRNewswire/ ExEm® Foam Inc announced today that ExEm® Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for ultrasound tubal patency testing, is now available at select fertility clinics nationwide. The Foam procedure, a new ultrasound technique of hysterosalpingo foam sonography (HyFoSy), uses ExEm® Foam to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. The innovative imaging technique offers a less complicated and less invasive alternative to laparoscopy and dye, the gold standard for diagnosing tubal patency. The outpatient tubal assessment is also associated with significantly lower pain scores as compared to the standard of care, X-ray hysterosalpingography (HSG), and does not require the use of radiation and iodine.